Alexander A Chumanevich
Overview
Explore the profile of Alexander A Chumanevich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
840
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hofseth L, Hebert J, Murphy E, Trauner E, Vikas A, Harris Q, et al.
Carcinogenesis
. 2024 Aug;
45(10):711-720.
PMID: 39129647
Merriam-Webster and Oxford define a xenobiotic as any substance foreign to living systems. Allura Red AC (a.k.a., E129; FD&C Red No. 40), a synthetic food dye extensively used in manufacturing...
2.
Li J, Hilimire T, Liu Y, Wang L, Liang J, Gyorffy B, et al.
J Clin Invest
. 2024 Mar;
134(10).
PMID: 38546787
Mediator kinases CDK19 and CDK8, pleiotropic regulators of transcriptional reprogramming, are differentially regulated by androgen signaling, but both kinases are upregulated in castration-resistant prostate cancer (CRPC). Genetic or pharmacological inhibition...
3.
Zhang Q, Chumanevich A, Nguyen I, Chumanevich A, Sartawi N, Hogan J, et al.
Toxicol Rep
. 2023 Sep;
11:221-232.
PMID: 37719200
The incidence of colorectal cancer (CRC) among young people has been on the rise for the past four decades and its underlying causes are only just starting to be uncovered....
4.
Zhang L, Cheng C, Li J, Wang L, Chumanevich A, Porter D, et al.
J Med Chem
. 2022 Feb;
65(4):3420-3433.
PMID: 35114084
Senexins are potent and selective quinazoline inhibitors of CDK8/19 Mediator kinases. To improve their potency and metabolic stability, quinoline-based derivatives were designed through a structure-guided strategy based on the simulated...
5.
Tashkandi H, Chaparala A, Peng S, Nagarkatti M, Nagarkatti P, Chumanevich A, et al.
J Cancer Sci Clin Ther
. 2020 Sep;
4(2):133-143.
PMID: 32905447
The purpose of our study is to explore the pharmacokinetic parameters of panaxynol (PA) and understand its potential and dosage used in pre-clinical animal models. For analysis,5 μM of PA...
6.
Molecules from American Ginseng Suppress Colitis through Nuclear Factor Erythroid-2-Related Factor 2
Chaparala A, Tashkandi H, Chumanevich A, Witalison E, Windust A, Cui T, et al.
Nutrients
. 2020 Jun;
12(6).
PMID: 32575883
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects millions of people worldwide and increases the risk of colorectal cancer (CRC) development. We have previously shown that American...
7.
Chaparala A, Poudyal D, Tashkandi H, Witalison E, Chumanevich A, Hofseth J, et al.
Oncotarget
. 2020 Jun;
11(22):2026-2036.
PMID: 32547701
Ulcerative colitis has a significant impact on the quality of life for the patients, and can substantially increase the risk of colon cancer in patients suffering long-term. Conventional treatments provide...
8.
Liang J, Chen M, Hughes D, Chumanevich A, Altilia S, Kaza V, et al.
Cancer Res
. 2018 Sep;
78(23):6594-6606.
PMID: 30185549
: Unresectable hepatic metastases of colon cancer respond poorly to existing therapies and are a major cause of colon cancer lethality. In this study, we evaluated the therapeutic viability of...
9.
Serrao A, Jenkins L, Chumanevich A, Horst B, Liang J, Gatza M, et al.
Oncogene
. 2018 May;
37(35):4792-4808.
PMID: 29780169
CDK8 is a transcription-regulating kinase that controls TGF-β/BMP-responsive SMAD transcriptional activation and turnover through YAP1 recruitment. However, how the CDK8/YAP1 pathway influences SMAD1 response in cancer remains unclear. Here we...
10.
McDermott M, Chumanevich A, Lim C, Liang J, Chen M, Altilia S, et al.
Oncotarget
. 2017 Feb;
8(8):12558-12575.
PMID: 28147342
Hormone therapy targeting estrogen receptor (ER) is the principal treatment for ER-positive breast cancers. However, many cancers develop resistance to hormone therapy while retaining ER expression. Identifying new druggable mediators...